Business · 14/02/2012Updated: 10/17/2026 · 1 min read
FDA's Dermatologic and Ophthalmic Drugs Advisory Committee to Review Amendment of Notice Regarding New Drug Applications
Summary
The FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will review an amendment to a notice regarding new drug applications, a process aimed at ensuring the safety and efficacy of new treatments for skin and eye conditions
Original source language: Federal Register — Food and Drug AdministrationOpen original release →